Cargando…

Serum tumor markers for the prediction of concordance between genomic profiles from liquid and tissue biopsy in patients with advanced lung adenocarcinoma

BACKGROUND: The concordance between mutations detected from plasma and tissue is critical for treatment choices of patients with advanced lung adenocarcinoma. METHODS: We prospectively analyzed the association of the serum tumor markers with the concordance between blood and tissue genomic profiles...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiao, Xiao-Dong, Ding, Li-Ren, Zhang, Chuan-Tao, Qin, Bao-Dong, Liu, Ke, Jiang, Lian-Ping, Wang, Xi, Lv, Li-Ting, Ding, Hao, Li, Dao-Ming, Yang, Hui, Chen, Xue-Qin, Zhu, Wen-Yu, Wu, Ying, Ling, Yan, He, Xi, Liu, Jun, Shao, Lin, Wang, Hao-Zhe, Chen, Yan, Zheng, Jing-Jing, Inui, Naoki, Zang, Yuan-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350084/
https://www.ncbi.nlm.nih.gov/pubmed/34430361
http://dx.doi.org/10.21037/tlcr-21-543
_version_ 1783735676968108032
author Jiao, Xiao-Dong
Ding, Li-Ren
Zhang, Chuan-Tao
Qin, Bao-Dong
Liu, Ke
Jiang, Lian-Ping
Wang, Xi
Lv, Li-Ting
Ding, Hao
Li, Dao-Ming
Yang, Hui
Chen, Xue-Qin
Zhu, Wen-Yu
Wu, Ying
Ling, Yan
He, Xi
Liu, Jun
Shao, Lin
Wang, Hao-Zhe
Chen, Yan
Zheng, Jing-Jing
Inui, Naoki
Zang, Yuan-Sheng
author_facet Jiao, Xiao-Dong
Ding, Li-Ren
Zhang, Chuan-Tao
Qin, Bao-Dong
Liu, Ke
Jiang, Lian-Ping
Wang, Xi
Lv, Li-Ting
Ding, Hao
Li, Dao-Ming
Yang, Hui
Chen, Xue-Qin
Zhu, Wen-Yu
Wu, Ying
Ling, Yan
He, Xi
Liu, Jun
Shao, Lin
Wang, Hao-Zhe
Chen, Yan
Zheng, Jing-Jing
Inui, Naoki
Zang, Yuan-Sheng
author_sort Jiao, Xiao-Dong
collection PubMed
description BACKGROUND: The concordance between mutations detected from plasma and tissue is critical for treatment choices of patients with advanced lung adenocarcinoma. METHODS: We prospectively analyzed the association of the serum tumor markers with the concordance between blood and tissue genomic profiles from 185 patients with advanced lung adenocarcinoma. The concordance was defined according to 3 criteria. Class 1 included all targetable driver mutations in 8 genes; class 2 included class 1 mutations plus mutations in KRAS, STK11, and TP53; class 3 included class 2 mutations plus tumor mutation burden (TMB) status. RESULTS: Collectively, 150 out of 185 patients had mutations in both tissue and plasma samples, while one patient was mutation-negative for both, resulting a concordance of 81.6%. The concordance rate for class 1 mutations was 80%, and 65% and 69% for class 2 and class 3, respectively. Carbohydrate antigen 19-9 (CA19-9) or cytokeratin 19 (CYFRA21-1) levels higher than the normal upper limit predicted the concordance of tissue and blood results in class 1 (P=0.005, P=0.011), class 2 (P=0.011, P<0.001), and class 3 (P=0.001, P=0.014). In class 1, the cutoff values of CA19-9 were 30, 36, and 284 U/mL to reach the concordance thresholds of 90%, 95%, and 100%, respectively (P=0.032, P=0.003, P=0.043). For CYFRA21-1, the cutoff values were 6, 18, and 52 µg/L (P=0.005, P=0.051, P=0.354). In class 2, the cutoff values for CYFRA21-1 were 18, 22, and 52 µg/L (P=0.001, P=0.001, P=0.052). In class 3, the cutoff values for CA19-9 were 36, 39, and 85 U/mL (P=0.003, P=0.001, P=0.008). For CYFRA21-1, the cutoff values were 22, 52, and 52 µg/L (P=0.900, P>0.99, P>0.99). When the sum score for 4 serum tumor markers was greater than 35, both class 1, class 2, and class 3 reached a predictive threshold of 90%. CONCLUSIONS: Serum tumor markers can be used as easy and practical clinical predictors of concordance in mutation profiles between blood and tissue samples from patients with advanced lung adenocarcinoma.
format Online
Article
Text
id pubmed-8350084
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-83500842021-08-23 Serum tumor markers for the prediction of concordance between genomic profiles from liquid and tissue biopsy in patients with advanced lung adenocarcinoma Jiao, Xiao-Dong Ding, Li-Ren Zhang, Chuan-Tao Qin, Bao-Dong Liu, Ke Jiang, Lian-Ping Wang, Xi Lv, Li-Ting Ding, Hao Li, Dao-Ming Yang, Hui Chen, Xue-Qin Zhu, Wen-Yu Wu, Ying Ling, Yan He, Xi Liu, Jun Shao, Lin Wang, Hao-Zhe Chen, Yan Zheng, Jing-Jing Inui, Naoki Zang, Yuan-Sheng Transl Lung Cancer Res Original Article BACKGROUND: The concordance between mutations detected from plasma and tissue is critical for treatment choices of patients with advanced lung adenocarcinoma. METHODS: We prospectively analyzed the association of the serum tumor markers with the concordance between blood and tissue genomic profiles from 185 patients with advanced lung adenocarcinoma. The concordance was defined according to 3 criteria. Class 1 included all targetable driver mutations in 8 genes; class 2 included class 1 mutations plus mutations in KRAS, STK11, and TP53; class 3 included class 2 mutations plus tumor mutation burden (TMB) status. RESULTS: Collectively, 150 out of 185 patients had mutations in both tissue and plasma samples, while one patient was mutation-negative for both, resulting a concordance of 81.6%. The concordance rate for class 1 mutations was 80%, and 65% and 69% for class 2 and class 3, respectively. Carbohydrate antigen 19-9 (CA19-9) or cytokeratin 19 (CYFRA21-1) levels higher than the normal upper limit predicted the concordance of tissue and blood results in class 1 (P=0.005, P=0.011), class 2 (P=0.011, P<0.001), and class 3 (P=0.001, P=0.014). In class 1, the cutoff values of CA19-9 were 30, 36, and 284 U/mL to reach the concordance thresholds of 90%, 95%, and 100%, respectively (P=0.032, P=0.003, P=0.043). For CYFRA21-1, the cutoff values were 6, 18, and 52 µg/L (P=0.005, P=0.051, P=0.354). In class 2, the cutoff values for CYFRA21-1 were 18, 22, and 52 µg/L (P=0.001, P=0.001, P=0.052). In class 3, the cutoff values for CA19-9 were 36, 39, and 85 U/mL (P=0.003, P=0.001, P=0.008). For CYFRA21-1, the cutoff values were 22, 52, and 52 µg/L (P=0.900, P>0.99, P>0.99). When the sum score for 4 serum tumor markers was greater than 35, both class 1, class 2, and class 3 reached a predictive threshold of 90%. CONCLUSIONS: Serum tumor markers can be used as easy and practical clinical predictors of concordance in mutation profiles between blood and tissue samples from patients with advanced lung adenocarcinoma. AME Publishing Company 2021-07 /pmc/articles/PMC8350084/ /pubmed/34430361 http://dx.doi.org/10.21037/tlcr-21-543 Text en 2021 Translational Lung Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Jiao, Xiao-Dong
Ding, Li-Ren
Zhang, Chuan-Tao
Qin, Bao-Dong
Liu, Ke
Jiang, Lian-Ping
Wang, Xi
Lv, Li-Ting
Ding, Hao
Li, Dao-Ming
Yang, Hui
Chen, Xue-Qin
Zhu, Wen-Yu
Wu, Ying
Ling, Yan
He, Xi
Liu, Jun
Shao, Lin
Wang, Hao-Zhe
Chen, Yan
Zheng, Jing-Jing
Inui, Naoki
Zang, Yuan-Sheng
Serum tumor markers for the prediction of concordance between genomic profiles from liquid and tissue biopsy in patients with advanced lung adenocarcinoma
title Serum tumor markers for the prediction of concordance between genomic profiles from liquid and tissue biopsy in patients with advanced lung adenocarcinoma
title_full Serum tumor markers for the prediction of concordance between genomic profiles from liquid and tissue biopsy in patients with advanced lung adenocarcinoma
title_fullStr Serum tumor markers for the prediction of concordance between genomic profiles from liquid and tissue biopsy in patients with advanced lung adenocarcinoma
title_full_unstemmed Serum tumor markers for the prediction of concordance between genomic profiles from liquid and tissue biopsy in patients with advanced lung adenocarcinoma
title_short Serum tumor markers for the prediction of concordance between genomic profiles from liquid and tissue biopsy in patients with advanced lung adenocarcinoma
title_sort serum tumor markers for the prediction of concordance between genomic profiles from liquid and tissue biopsy in patients with advanced lung adenocarcinoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350084/
https://www.ncbi.nlm.nih.gov/pubmed/34430361
http://dx.doi.org/10.21037/tlcr-21-543
work_keys_str_mv AT jiaoxiaodong serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma
AT dingliren serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma
AT zhangchuantao serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma
AT qinbaodong serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma
AT liuke serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma
AT jianglianping serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma
AT wangxi serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma
AT lvliting serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma
AT dinghao serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma
AT lidaoming serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma
AT yanghui serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma
AT chenxueqin serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma
AT zhuwenyu serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma
AT wuying serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma
AT lingyan serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma
AT hexi serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma
AT liujun serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma
AT shaolin serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma
AT wanghaozhe serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma
AT chenyan serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma
AT zhengjingjing serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma
AT inuinaoki serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma
AT zangyuansheng serumtumormarkersforthepredictionofconcordancebetweengenomicprofilesfromliquidandtissuebiopsyinpatientswithadvancedlungadenocarcinoma